RS51068B - Derivati-5-piridinil-1-azabiciklo[3.2.1]oktana, njihovo dobijanje i njihova terapeutska primena - Google Patents

Derivati-5-piridinil-1-azabiciklo[3.2.1]oktana, njihovo dobijanje i njihova terapeutska primena

Info

Publication number
RS51068B
RS51068B RSP-2009/0576A RSP20090576A RS51068B RS 51068 B RS51068 B RS 51068B RS P20090576 A RSP20090576 A RS P20090576A RS 51068 B RS51068 B RS 51068B
Authority
RS
Serbia
Prior art keywords
therapeutics
same
azabicyclo
pyridinyl
octane
Prior art date
Application number
RSP-2009/0576A
Other languages
English (en)
Inventor
Frédéric Galli
Odile Leclerc
Alistair Lochead
Julien Vache
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36273387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51068(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of RS51068B publication Critical patent/RS51068B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Jedinjenja koja odgovaraju formuli (I)u kojoj:R predstavlja grupu odabranu od pirazolila, imidazolila, triazolila, oksazolila, oksadiazolila, tiazolila, izo-tiazolila, tiadiazolila, tetrazolila. Ova grupa može eventualno biti supstituisana jednom ili više grupa odabranih od atoma halogena, grupa (C1-C6)alkil, (C1-C6)alkoksi, trifluorometoksi, trifluorometil, nitro, cijano, hidroksi, amino, (C1-C6)alkilamino ili di(C1-C6)alkilamino; veza između ugljenika na položajima 3 i 4 prstena azabiciklo oktana je jednoguba ili dvogubau vidu baze ili adicione soli kiseline, kao i u stanju hidrata ili solvata.Prijava sadrži još 20 zavisnih patentnih zahteva.
RSP-2009/0576A 2005-08-12 2006-08-07 Derivati-5-piridinil-1-azabiciklo[3.2.1]oktana, njihovo dobijanje i njihova terapeutska primena RS51068B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508528A FR2889701B1 (fr) 2005-08-12 2005-08-12 Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation en therapeutique.
PCT/FR2006/001912 WO2007020344A1 (fr) 2005-08-12 2006-08-07 DÉRIVÉS DE δ-PYRIDINYL-i-AZABICYCLO[3.2.1]OCTANE, A LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE

Publications (1)

Publication Number Publication Date
RS51068B true RS51068B (sr) 2010-10-31

Family

ID=36273387

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0576A RS51068B (sr) 2005-08-12 2006-08-07 Derivati-5-piridinil-1-azabiciklo[3.2.1]oktana, njihovo dobijanje i njihova terapeutska primena

Country Status (41)

Country Link
US (2) US7863290B2 (sr)
EP (1) EP1915375B1 (sr)
JP (1) JP5164841B2 (sr)
KR (1) KR101299339B1 (sr)
CN (1) CN101238125B (sr)
AT (1) ATE444964T1 (sr)
AU (1) AU2006281341B2 (sr)
BR (1) BRPI0614623A2 (sr)
CA (1) CA2617828C (sr)
CR (1) CR9625A (sr)
CY (1) CY1109717T1 (sr)
DE (1) DE602006009668D1 (sr)
DK (1) DK1915375T3 (sr)
DO (1) DOP2006000180A (sr)
EA (1) EA014023B1 (sr)
EC (1) ECSP088170A (sr)
ES (1) ES2332472T3 (sr)
FR (1) FR2889701B1 (sr)
GT (1) GT200600368A (sr)
HK (1) HK1120788A1 (sr)
HN (1) HN2008000090A (sr)
HR (1) HRP20090677T1 (sr)
IL (1) IL188796A (sr)
JO (1) JO2583B1 (sr)
MA (1) MA30200B1 (sr)
ME (1) ME01750B (sr)
MX (1) MX2008001968A (sr)
MY (1) MY147846A (sr)
NO (1) NO20081151L (sr)
NZ (1) NZ565149A (sr)
PE (1) PE20070339A1 (sr)
PL (1) PL1915375T3 (sr)
PT (1) PT1915375E (sr)
RS (1) RS51068B (sr)
SI (1) SI1915375T1 (sr)
TN (1) TNSN07472A1 (sr)
TW (1) TWI324158B (sr)
UA (1) UA92917C2 (sr)
UY (1) UY29744A1 (sr)
WO (1) WO2007020344A1 (sr)
ZA (1) ZA200800958B (sr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912404B1 (fr) * 2007-02-09 2009-04-10 Sanofi Aventis Sa Derives d'azabicycloalkane,leur preparation et leur application en therapeutique.
GB0817424D0 (en) 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
JP2017114765A (ja) * 2014-04-25 2017-06-29 大正製薬株式会社 トリアゾリルで置換されたヘテロアリール化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
EP0664293A1 (en) * 1993-12-24 1995-07-26 Duphar International Research B.V 2-Phenyl-7-azabicycloheptanes and 6-phenyl-8-azabicyclo
KR100589872B1 (ko) * 1997-05-30 2006-06-15 뉴로서치 에이/에스 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법
FR2834511B1 (fr) 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
SI1915375T1 (sl) 2010-01-29
HN2008000090A (es) 2010-08-19
ZA200800958B (en) 2009-04-29
US20080146608A1 (en) 2008-06-19
BRPI0614623A2 (pt) 2011-04-12
US8541440B2 (en) 2013-09-24
AU2006281341A1 (en) 2007-02-22
CN101238125B (zh) 2012-07-04
IL188796A0 (en) 2008-08-07
CR9625A (es) 2008-04-10
JP5164841B2 (ja) 2013-03-21
TW200740810A (en) 2007-11-01
DK1915375T3 (da) 2010-02-15
MA30200B1 (fr) 2009-02-02
HK1120788A1 (sr) 2009-04-09
EP1915375B1 (fr) 2009-10-07
EA014023B1 (ru) 2010-08-30
HRP20090677T1 (hr) 2010-01-31
NZ565149A (en) 2011-05-27
MX2008001968A (es) 2008-03-26
UA92917C2 (uk) 2010-12-27
EA200800575A1 (ru) 2008-06-30
EP1915375A1 (fr) 2008-04-30
US7863290B2 (en) 2011-01-04
WO2007020344A1 (fr) 2007-02-22
CN101238125A (zh) 2008-08-06
ECSP088170A (es) 2008-03-26
CY1109717T1 (el) 2014-08-13
JP2009505971A (ja) 2009-02-12
FR2889701B1 (fr) 2007-10-05
CA2617828A1 (fr) 2007-02-22
KR20080033378A (ko) 2008-04-16
DOP2006000180A (es) 2007-02-28
PL1915375T3 (pl) 2010-03-31
US20110077264A1 (en) 2011-03-31
PT1915375E (pt) 2009-11-26
JO2583B1 (en) 2011-02-27
NO20081151L (no) 2008-05-13
TNSN07472A1 (en) 2009-03-17
IL188796A (en) 2012-09-24
TWI324158B (en) 2010-05-01
CA2617828C (fr) 2014-03-11
MY147846A (en) 2013-01-31
FR2889701A1 (fr) 2007-02-16
PE20070339A1 (es) 2007-04-18
GT200600368A (es) 2007-07-06
ES2332472T3 (es) 2010-02-05
ATE444964T1 (de) 2009-10-15
KR101299339B1 (ko) 2013-08-26
ME01750B (me) 2010-10-31
UY29744A1 (es) 2007-03-30
DE602006009668D1 (de) 2009-11-19
AU2006281341B2 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
WO2004096134A3 (en) Substituted 1,4-diazepines and uses thereof
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
WO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2006077025A3 (en) Morpholines as 5ht2c agonists
ZA200609634B (en) Quinazolinone derivatives useful as vanilloid antagonists
WO2009025239A1 (ja) 新規外用剤
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
MX2010003495A (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas.
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
RS20060239A (en) Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics
WO2007080324A3 (fr) Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
IL188796A0 (en) Derivatives of 5-pyridinyl-1-azabicyclo[3,2,1] octane, preparation method thereof and use of same in therapeutics
WO2005033279A3 (en) Discovery of novel soluble crystalline anesthetics
TW200800983A (en) 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
UA92360C2 (en) Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics
UA104302C2 (ru) Производные морфин-6-глюкуронида, их получение и их применение в терапии
HK1101170A1 (en) Method for cleaning 3-hydroxyamidinophenylalanine derivatives by the precipitation and recrystallisation of a salt and an aromatic sulphonic acid
WO2010067008A3 (fr) Derives bicycliques de morphine-6-glucuronide, leur preparation et leur application en therapeutique
WO2005076747A3 (en) Double salts of (-)-hydroxycitric acid with an amine and a group ii a metal and a process for preparing the same